Trident Lifeline Ltd
Incorporated in 2014, Trident Lifeline Ltd manufactures and sells pharmaceuticals
products[1]
- Market Cap ₹ 327 Cr.
- Current Price ₹ 284
- High / Low ₹ 339 / 140
- Stock P/E 27.5
- Book Value ₹ 51.4
- Dividend Yield 0.00 %
- ROCE 19.1 %
- ROE 14.3 %
- Face Value ₹ 10.0
Pros
- Company is expected to give good quarter
Cons
- Though the company is reporting repeated profits, it is not paying out dividend
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Bulk Drugs & Formln
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | TTM | |
|---|---|---|---|---|---|---|
| 5 | 10 | 22 | 32 | 45 | 66 | |
| 5 | 8 | 19 | 25 | 36 | 50 | |
| Operating Profit | -0 | 1 | 3 | 6 | 9 | 16 |
| OPM % | -5% | 13% | 12% | 20% | 20% | 24% |
| 0 | 0 | 1 | 1 | 2 | 3 | |
| Interest | 1 | 0 | 0 | 0 | 1 | 1 |
| Depreciation | 0 | 0 | 0 | 0 | 1 | 1 |
| Profit before tax | -1 | 1 | 3 | 7 | 10 | 16 |
| Tax % | -26% | 26% | -32% | 9% | 28% | |
| -1 | 1 | 4 | 6 | 7 | 12 | |
| EPS in Rs | -2.58 | 1.26 | 4.94 | 5.23 | 6.12 | 10.33 |
| Dividend Payout % | -0% | -0% | -0% | -0% | -0% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 67% |
| TTM: | 93% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 123% |
| TTM: | 92% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | 72% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 22% |
| Last Year: | 14% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Sep 2024 | |
|---|---|---|---|---|---|---|
| Equity Capital | 3 | 5 | 8 | 12 | 12 | 12 |
| Reserves | -6 | -5 | -3 | 34 | 41 | 48 |
| 6 | 5 | 2 | 3 | 6 | 9 | |
| 3 | 7 | 7 | 7 | 14 | 16 | |
| Total Liabilities | 6 | 11 | 14 | 56 | 73 | 84 |
| 1 | 1 | 1 | 3 | 8 | 13 | |
| CWIP | -0 | -0 | -0 | 0 | 4 | 1 |
| Investments | -0 | -0 | 0 | 4 | 4 | 5 |
| 6 | 10 | 12 | 49 | 57 | 65 | |
| Total Assets | 6 | 11 | 14 | 56 | 73 | 84 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
|---|---|---|---|---|---|
| -1 | 1 | -0 | -17 | 1 | |
| -0 | -1 | -0 | -6 | -11 | |
| 1 | -1 | 1 | 36 | 2 | |
| Net Cash Flow | 0 | -0 | 0 | 14 | -8 |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
|---|---|---|---|---|---|
| Debtor Days | 97 | 24 | 83 | 140 | 112 |
| Inventory Days | 104 | 349 | 95 | 129 | 137 |
| Days Payable | 202 | 266 | 134 | 87 | 94 |
| Cash Conversion Cycle | -1 | 107 | 44 | 183 | 155 |
| Working Capital Days | -12 | 12 | 67 | 307 | 267 |
| ROCE % | 34% | 55% | 25% | 19% |
Documents
Announcements
-
Board Meeting Intimation for Approval Of Audited Standalone And Consolidated Financial Results For The Half Year And Year Ended 31St March, 2025
2d - Board meeting on April 28 to approve FY25 audited financial results; trading window closed till then.
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
18 Apr - Copies of newspaper advertisements published in the Financial Express (English) and Financial Express (Gujarati), regarding notice of Extra Ordinary General Meeting.
-
Shareholder''s Meeting-EGM-09-05-2025
17 Apr - EOGM for Rs. 26.57 Cr preferential issue and increase in authorized share capital.
-
Regulation 30 Of The SEBI (LODR) Regulations, 2015
17 Apr - Further allotment in subsidiary; shareholding remains at 51%.
-
Announcement under Regulation 30 (LODR)-Issue of Securities
16 Apr - Preferential issue of 9.99 lakh warrants; increase in authorized share capital.
Business Overview:[1]
TFL is a pharmaceutical Company with business operations spanning formulations under its own brands, loan licence model and contract manufacturing model.
a) Pharmaceutical formulations export:
Company has a presence in 40 countries, including African, Latin America, and East
Asian countries, with ~945 registered export market products, and ~2016 export market products are under registration
b) Contract manufacturing:
Company follows an Asset-light third-party contract manufacturing model thus entailing limited direct investment in manufacturing capacities